These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7098411)

  • 21. [The effect of kavinton on bronchial tonus in bronchial asthma patients].
    Karashurov SE
    Eksp Klin Farmakol; 1994; 57(6):35-6. PubMed ID: 7756957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of severe motion sickness with antimotion sickness drug injections.
    Graybiel A; Lackner JR
    Aviat Space Environ Med; 1987 Aug; 58(8):773-6. PubMed ID: 3632537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of phenytoin on vection-induced motion sickness and gastric myoelectric activity.
    Stern RM; Uijtdehaage SH; Muth ER; Koch KL
    Aviat Space Environ Med; 1994 Jun; 65(6):518-21. PubMed ID: 8074624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and treatment of space sickness in shuttle-orbiter missions.
    Graybiel A
    Aviat Space Environ Med; 1979 Feb; 50(2):171-6. PubMed ID: 36067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promethazine as a motion sickness treatment: impact on human performance and mood states.
    Cowings PS; Toscano WB; DeRoshia C; Miller NE
    Aviat Space Environ Med; 2000 Oct; 71(10):1013-22. PubMed ID: 11051308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chlorpheniramine for motion sickness.
    Buckey JC; Alvarenga D; Cole B; Rigas JR
    J Vestib Res; 2004; 14(1):53-61. PubMed ID: 15156097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Motion sickness: acquisition and retention of adaptation effects compared in three motion environments.
    Graybiel A; Lackner JR
    Aviat Space Environ Med; 1983 Apr; 54(4):307-11. PubMed ID: 6847566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms.
    Cowings PS; Toscano WB
    J Clin Pharmacol; 2000 Oct; 40(10):1154-65. PubMed ID: 11028255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of phosphatidylcholine in the modulation of motion sickness susceptibility.
    Kohl RL; Ryan P; Homick JL
    Aviat Space Environ Med; 1985 Feb; 56(2):125-8. PubMed ID: 3985888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prevention of motion sickness in orbital flight.
    Graybiel A
    Life Sci Space Res; 1976; 14():109-18. PubMed ID: 11977268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arousal and stability: the effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness.
    Kohl RL; Calkins DS; Mandell AJ
    Aviat Space Environ Med; 1986 Feb; 57(2):137-43. PubMed ID: 3513752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenytoin for motion sickness: clinical evaluation.
    Knox GW; Woodard D; Chelen W; Ferguson R; Johnson L
    Laryngoscope; 1994 Aug; 104(8 Pt 1):935-9. PubMed ID: 8052077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Modelling of the space form of motion sickness].
    Galle RR; Kotovskaia AR; Gusakova GA; Gavrilova LN; Galle NN
    Kosm Biol Aviakosm Med; 1983; 17(3):74-8. PubMed ID: 6876724
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of a new antinauseant drug for the prevention of motion sickness.
    Graybiel A; Knepton J
    Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151
    [No Abstract]   [Full Text] [Related]  

  • 38. Control of simulator sickness in an AH-64 aviator.
    Kroll JD
    Aviat Space Environ Med; 1989 Dec; 60(12):1202-3. PubMed ID: 2604677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and duration of intramuscular antimotion sickness medications.
    Wood CD; Stewart JJ; Wood MJ; Mims M
    J Clin Pharmacol; 1992 Nov; 32(11):1008-12. PubMed ID: 1474161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD; Rapaport MH
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.